Serono Symposia International Foundation adheres to guidelines of the European Accreditation Council for Continuing Medical Education (EACCME) and all other professional organizations, as applicable, which state that programs awarding continuing education credits must be balanced, independent, objective, and scientifically rigorous. Investigative and other uses for pharmaceutical agents, medical devices, and other products (other than those uses indicated in approved product labeling/package insert for the product) may be presented in the program (which may reflect clinical experience, the professional literature or other clinical sources known to the presenter). We ask all presenters to provide participants with information about relationships with pharmaceutical or medical equipment companies that may have relevance to their lectures. This policy is not intended to exclude faculty who have relationships with such companies; it is only intended to inform participants of any potential conflicts so participants may form their own judgments, based on full disclosure of the facts. Further, all opinions and recommendations presented during the program and all program-related materials neither imply an endorsement, nor a recommendation, on the part of Serono Symposia International Foundation. All presentations solely represent the independent views of the presenters/authors.
The following faculty indicated no significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Pierre Duquette
Gilles Edan
The following faculty provided information regarding significant commercial relationships and/or discussions of investigational or non- EMEA/FDA approved (off-label) uses of drugs:
Jack Antel: Declared receipt of research support from Novartis, Teva, Biogen. Serve on multiple Data Safety Monitoring Boards for clinical trials (Sanofi, Bayhill, BioMS, Teva).
Joseph R. Berger: Declared receipt of grants and contracts from EMD Serono and Pfizer and honoraria or consultation fees from EMD Serono, Bayer, Teva and Millenium. He declared also participation in a EMD Serono, Bayer and Teva sponsored speaker’s bureau.
Giancarlo Comi: Declared receipt of honoraria or consultation fees from Serono Symposia International Foundation, Merck Serono, Novartis, Teva Pharmaceutical Ind. Ltd., Sanof-Aventis, Biogen Dompè.
Mark S. Freedman: Declared receipt of honoraria or consultation fees from EMD Serono, Bayer Healthcare, Teva, Biogen Idec, Genentech, Sanofi-Aventis, Bio MS and Novartis. He declared also to member of Sanofi-Aventis and Novartis advisory boards and participation in a Pfizer sponsored speaker’s bureau.
Nils Koch-Henriksen: Declared receipt of grants and contracts (not personal) from Bayer-Schering, Merck Serono, Biogen Idec and Aventis (for the Danish MS treatment Register) and honoraria from Biogen Idec for lecturing at one occasion.
Fred D. Lublin: Declared receipt of grants and contracts from Teva, Biogen Idec, Acorda, Novartis, Genentech, Novartis, Genentech and honoraria or consultation fees from Teva, Biogen, EMD Serono, Pfizer, Novartis, Genentech, Genmab, Berlex, Actelion and Avigen. He declared also to be stakeholder in Cognition Pharma and participation in a Teva, Pfizer and EMD Serono sponsored speaker’s bureau.
Mar Tintoré: Declared receipt of grants and contracts and honoraria or consultation fees from Bayer Schering, Biogen Idec, Merck Serono and Teva Sanofi. She declared also to be member in a Teva Sanofi advisory board.
